The Administrative Planning and Evaluation Core, Core A, is critical to the success of the SPORE. Dr. Elizabeth Grimm is the overall Core Director, and is assisted by three Co-Directors, including the founding Co-Director, Dr. Jeffrey E. Lee, who will chair the Executive Committee meetings which will be composed of all Co-PIs and one leader from each Project and Core. Two new co-directors include Patrick Hwu, M.D., as director of the Clinical Trials Resource which for now will be incorporated as part of Core A;and Jeffrey E. Gershenwald, M.D., as overall director of patient informatics and tumor acquisition and distribution. Our Executive Committee will meet monthly to review scientific progress and fiscal status and will help surmount problems or barriers to assure that all goals are met within a realistic timeframe and within the budget constraints. This Administrative Core will schedule all meetings with investigators and assure optimum communication with investigators at M.D. Anderson Cancer Center and elsewhere. All SPORE investigators will participate in weekly melanoma seminars and regulariy report progress to the Internal Advisory Committee. An External Advisory Committee will evaluate status and progress of all SPORE research programs by annual meetings either in Houston or by web/video or teleconference. Specific responsibilities of Core A include * Compliance with all general, governmental and NCI regulations and requirements. * Communication and consultation with the NCI in preparation of all required reports and publications. * Coordination of data control quality assurance issues * Oversight and support for the Informatics, Tissue Resource and Pathology Core B. * Optimization of clinical trial efforts by a Clinical Trials Management Resource in this Core A. * Maintenance of fiscal and budgetary functions, and managing flexibility in funding. * Convene SPORE Administrative meetings, including the Executive Committee, the Internal and External Advisory Committees, weekly scientific meetings, quarteriy research meetings, lectures, and symposia. * Administration of the Developmental Research and Career Development Programs. * Coordination and Funding of Patient Advocate activities. * Establishment and monitoring of policies for recruitment of women and minorities of this program. * Coordination with other SPORE sites to promote and maintain communication and integration through sponsoring and/or attending a yeariy Skin SPORE conference, and also through sharing and distribution of materials, electronic communications, and evaluation of progress reports.

Public Health Relevance

This Administrative, Evaluation, and Planning Core will orchestrate the administrative aspects required for successful translation of our findings applicable to improving the lives of patients with melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA093459-07
Application #
8327831
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
7
Fiscal Year
2011
Total Cost
$160,645
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Teerlink, Craig C; Huff, Chad; Stevens, Jeff et al. (2018) A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma. J Natl Cancer Inst :
Bezrookove, Vladimir; Nosrati, Mehdi; Miller 3rd, James R et al. (2018) Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clin Cancer Res 24:4119-4125
Oba, Junna; Kim, Sun-Hee; Wang, Wei-Lien et al. (2018) Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol 2018:
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Hailemichael, Yared; Woods, Amber; Fu, Tihui et al. (2018) Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest 128:1338-1354
Antczak, Nicole M; Walker, Alice R; Stern, Hannah R et al. (2018) Characterization of Nine Cancer-Associated Variants in Human DNA Polymerase ?. Chem Res Toxicol 31:697-711
(2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50:668-681
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
Kim, Sun-Hee; Roszik, Jason; Cho, Sung-Nam et al. (2018) The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma. Clin Cancer Res :

Showing the most recent 10 out of 290 publications